Insider · CIK 0001825376

RA Capital Nexus Fund II, L.P.

CIK 0001825376 Name as filed on the most recent filing

Filed as RA Capital Nexus Fund II, L.P. (41)

87 transaction lines · from 41 filings · filed 2021-07-08 to 2026-05-06 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-05-06 P, Open-market purchase Hemab Therapeutics Holdings, Inc.COAG 2 lines 1,673,399, acquired Open Form 4 filing 0001231919-26-000457
2026-05-05 P, Open-market purchase Hemab Therapeutics Holdings, Inc.COAG 2 lines 2,399,546, acquired Open Form 4 filing 0001231919-26-000457
2026-05-04 P, Open-market purchase Hemab Therapeutics Holdings, Inc.COAG 2 lines 48,150,000, acquired Open Form 4 filing 0001231919-26-000457
2026-01-05 P, Open-market purchase Climb Bio, Inc.CLYM 24,889, acquired Open Form 4 filing 0001231919-26-000018
2025-12-12 P, Open-market purchase Climb Bio, Inc.CLYM 290,181, acquired Open Form 4 filing 0001231919-25-000616
2025-12-11 P, Open-market purchase Climb Bio, Inc.CLYM 464,556, acquired Open Form 4 filing 0001231919-25-000616
2025-09-26 P, Open-market purchase PepGen Inc.PEPG 30,000,000, acquired Open Form 4 filing 0001231919-25-000265
2025-05-14 P, Open-market purchase Werewolf Therapeutics, Inc.HOWL 159,288, acquired Open Form 4 filing 0001415889-25-012942
2025-05-13 P, Open-market purchase Werewolf Therapeutics, Inc.HOWL 51,915, acquired Open Form 4 filing 0001415889-25-012942
2025-05-12 P, Open-market purchase Werewolf Therapeutics, Inc.HOWL 275,985, acquired Open Form 4 filing 0001415889-25-012942
2025-03-07 P, Open-market purchase Janux Therapeutics, Inc.JANX 3,418,590, acquired Open Form 4 filing 0001415889-25-007443
2025-03-06 P, Open-market purchase Janux Therapeutics, Inc.JANX 11,453,023, acquired Open Form 4 filing 0001415889-25-007443
2025-03-05 P, Open-market purchase Janux Therapeutics, Inc.JANX 2 lines 10,471,352, acquired Open Form 4 filing 0001415889-25-007443
2024-10-18 P, Open-market purchase Janux Therapeutics, Inc.JANX 53,700,000, acquired Open Form 4 filing 0001415889-24-025502
2024-08-09 S, Open-market sale An2 Therapeutics, Inc.ANTX 2 lines 3,807,102, disposed Open Form 4 filing 0001415889-24-021199
2024-06-27 P, Open-market purchase Eliem Therapeutics, Inc.ELYM 2 lines 49,952,817, acquired Open Form 4 filing 0001415889-24-018708
2024-04-02 P, Open-market purchase Boundless Bio, Inc.BOLD 2 lines 5,000,000, acquired Open Form 4 filing 0001415889-24-010278
2024-03-27 P, Open-market purchase ARS Pharmaceuticals, Inc.SPRY 4,953,290, acquired Open Form 4 filing 0001415889-24-009268
2024-03-26 P, Open-market purchase ARS Pharmaceuticals, Inc.SPRY 4,371,465, acquired Open Form 4 filing 0001415889-24-009268
2024-03-25 P, Open-market purchase ARS Pharmaceuticals, Inc.SPRY 3,964,656, acquired Open Form 4 filing 0001415889-24-009268
2024-03-21 P, Open-market purchase Lenz Therapeutics, Inc.LENZ 2 lines 15,000,075, acquired Open Form 4 filing 0001415889-24-009077
2024-02-09 P, Open-market purchase PepGen Inc.PEPG 27,212,790, acquired Open Form 4 filing 0001209191-24-003175
2023-09-21 P, Open-market purchase ARS Pharmaceuticals, Inc.SPRY 2 lines 8,183,526, acquired Open Form 4 filing 0001104659-23-103529
2023-08-29 P, Open-market purchase ARS Pharmaceuticals, Inc.SPRY 23,250,000, acquired Open Form 4 filing 0001104659-23-097327
2023-08-18 P, Open-market purchase An2 Therapeutics, Inc.ANTX 16,000,002, acquired Open Form 4 filing 0001104659-23-094274
2023-07-21 P, Open-market purchase Acumen Pharmaceuticals, Inc.ABOS 39,999,998, acquired Open Form 4 filing 0001104659-23-083857
2023-07-19 P, Open-market purchase Janux Therapeutics, Inc.JANX 6,167,800, acquired Open Form 4 filing 0001104659-23-083069
2023-03-30 P, Open-market purchase Dice Therapeutics, Inc.DICE 5,632,954, acquired Open Form 4 filing 0001104659-23-039250
2023-03-29 P, Open-market purchase Dice Therapeutics, Inc.DICE 1,949,921, acquired Open Form 4 filing 0001104659-23-039250
2023-03-28 P, Open-market purchase Dice Therapeutics, Inc.DICE 7,215,818, acquired Open Form 4 filing 0001104659-23-039250
2023-03-27 P, Open-market purchase Dice Therapeutics, Inc.DICE 4,153,107, acquired Open Form 4 filing 0001104659-23-037172
2023-03-24 P, Open-market purchase Dice Therapeutics, Inc.DICE 5,168,041, acquired Open Form 4 filing 0001104659-23-037172
2023-03-23 P, Open-market purchase Dice Therapeutics, Inc.DICE 4,136,224, acquired Open Form 4 filing 0001104659-23-037172
2022-11-17 P, Open-market purchase Acrivon Therapeutics, Inc.ACRV 42,368,750, acquired Open Form 4 filing 0001104659-22-120780
2022-10-17 P, Open-market purchase Dice Therapeutics, Inc.DICE 59,860,000, acquired Open Form 4 filing 0001104659-22-110000
2022-08-04 P, Open-market purchase An2 Therapeutics, Inc.ANTX 799, acquired Open Form 4 filing 0001104659-22-086686
2022-08-03 P, Open-market purchase An2 Therapeutics, Inc.ANTX 13,531, acquired Open Form 4 filing 0001104659-22-086686
2022-07-27 P, Open-market purchase An2 Therapeutics, Inc.ANTX 65,503, acquired Open Form 4 filing 0001104659-22-083728
2022-07-26 P, Open-market purchase An2 Therapeutics, Inc.ANTX 115,172, acquired Open Form 4 filing 0001104659-22-083728
2022-06-21 P, Open-market purchase An2 Therapeutics, Inc.ANTX 2,413, acquired Open Form 4 filing 0001104659-22-073920
2022-06-14 P, Open-market purchase An2 Therapeutics, Inc.ANTX 489,402, acquired Open Form 4 filing 0001104659-22-071465

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. RA Capital Nexus Fund II, L.P., insider transactions. Retrieved 2026-08-22 from https://ebomi.com/insider/0001825376

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.